Mubasher: UAE-based CE‑Ventures, the VC arm of Crescent Enterprises, has participated in a $55 million Series A funding round for US-based biotech company Think Bioscience, according to a press release.
The new capital will develop Think Bio’s internal pipeline of first-in-class small molecule programs and enhance its synthetic biology discovery platform.
The oversubscribed round was led by Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors, with participation from CE-Ventures, MBX Capital, T.A. Springer, and YK Bioventures, alongside returning investors AV8 Ventures, CU Innovations, and Buff Gold Ventures.
Tushar Singhvi, Deputy CEO and Head of Investments at Crescent Enterprises, said: “Our investment reflects strong conviction in Think Bio’s approach and the opportunity to build a leading biotech company that can benefit patients worldwide.”
Jerome Fox, Co-Founder and CEO at Think Bioscience, commented: “Our lead program has the potential to give a broad set of Noonan patients a normal life. We are grateful to our investors for supporting our vision to develop life-changing therapies for patients in need.”
Damir Illich, Manager, Life Sciences at CE-Ventures, noted: “Think Bioscience is addressing one of drug discovery’s most critical bottlenecks by enabling small-molecule drugs against historically undruggable targets. Their Noonan syndrome program highlights the platform’s potential where no approved therapies exist.”
